Cargando…
Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2)
SIMPLE SUMMARY: Salivary gland dysfunction is an underestimated late effect in childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch Childhood Cancer Survivor Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence o...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320024/ https://www.ncbi.nlm.nih.gov/pubmed/35884440 http://dx.doi.org/10.3390/cancers14143379 |
_version_ | 1784755692432785408 |
---|---|
author | Stolze, Juliette Teepen, Jop C. Raber-Durlacher, Judith E. Loonen, Jacqueline J. Kok, Judith L. Tissing, Wim J. E. de Vries, Andrica C. H. Neggers, Sebastian J. C. M. M. van Dulmen-den Broeder, Eline van den Heuvel-Eibrink, Marry M. van der Pal, Helena J. H. Versluys, A. Birgitta van der Heiden-van der Loo, Margriet Louwerens, Marloes Kremer, Leontien C. M. Brand, Henk S. Bresters, Dorine |
author_facet | Stolze, Juliette Teepen, Jop C. Raber-Durlacher, Judith E. Loonen, Jacqueline J. Kok, Judith L. Tissing, Wim J. E. de Vries, Andrica C. H. Neggers, Sebastian J. C. M. M. van Dulmen-den Broeder, Eline van den Heuvel-Eibrink, Marry M. van der Pal, Helena J. H. Versluys, A. Birgitta van der Heiden-van der Loo, Margriet Louwerens, Marloes Kremer, Leontien C. M. Brand, Henk S. Bresters, Dorine |
author_sort | Stolze, Juliette |
collection | PubMed |
description | SIMPLE SUMMARY: Salivary gland dysfunction is an underestimated late effect in childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch Childhood Cancer Survivor Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS with a long-term follow-up exceeding 15 years. From February 2016 until March 2020, 292 CCS were included. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia did not correlate significantly. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary glands. Screening for hyposalivation during long-term follow-up in CCS is recommended in order to provide optimal oral supportive care aimed to improve oral health. ABSTRACT: Background: Limited data are available on the risk factors of salivary gland dysfunction in long-term childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch CCS Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS. Methods: From February 2016 until March 2020, 292 CCS were included. Data with regard to gender, age at study, diagnosis, age at diagnosis, and treatment characteristics were collected, as well as the unstimulated (UWS) and stimulated whole salivary flow rate (SWS). Xerostomia was assessed with the Xerostomia Inventory (XI) questionnaire. Multivariable Poisson regression analyses were used to evaluate the association between potential risk factors and the occurrence of hyposalivation. Results: The minimum time between diagnosis and study enrollment was 15 years. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia were not significantly correlated. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary gland region. Conclusion: Considering the importance of saliva for oral health, screening for hyposalivation in CCS is suggested in order to provide optimal oral supportive care aimed to improve oral health. |
format | Online Article Text |
id | pubmed-9320024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93200242022-07-27 Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2) Stolze, Juliette Teepen, Jop C. Raber-Durlacher, Judith E. Loonen, Jacqueline J. Kok, Judith L. Tissing, Wim J. E. de Vries, Andrica C. H. Neggers, Sebastian J. C. M. M. van Dulmen-den Broeder, Eline van den Heuvel-Eibrink, Marry M. van der Pal, Helena J. H. Versluys, A. Birgitta van der Heiden-van der Loo, Margriet Louwerens, Marloes Kremer, Leontien C. M. Brand, Henk S. Bresters, Dorine Cancers (Basel) Article SIMPLE SUMMARY: Salivary gland dysfunction is an underestimated late effect in childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch Childhood Cancer Survivor Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS with a long-term follow-up exceeding 15 years. From February 2016 until March 2020, 292 CCS were included. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia did not correlate significantly. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary glands. Screening for hyposalivation during long-term follow-up in CCS is recommended in order to provide optimal oral supportive care aimed to improve oral health. ABSTRACT: Background: Limited data are available on the risk factors of salivary gland dysfunction in long-term childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch CCS Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS. Methods: From February 2016 until March 2020, 292 CCS were included. Data with regard to gender, age at study, diagnosis, age at diagnosis, and treatment characteristics were collected, as well as the unstimulated (UWS) and stimulated whole salivary flow rate (SWS). Xerostomia was assessed with the Xerostomia Inventory (XI) questionnaire. Multivariable Poisson regression analyses were used to evaluate the association between potential risk factors and the occurrence of hyposalivation. Results: The minimum time between diagnosis and study enrollment was 15 years. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia were not significantly correlated. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary gland region. Conclusion: Considering the importance of saliva for oral health, screening for hyposalivation in CCS is suggested in order to provide optimal oral supportive care aimed to improve oral health. MDPI 2022-07-11 /pmc/articles/PMC9320024/ /pubmed/35884440 http://dx.doi.org/10.3390/cancers14143379 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stolze, Juliette Teepen, Jop C. Raber-Durlacher, Judith E. Loonen, Jacqueline J. Kok, Judith L. Tissing, Wim J. E. de Vries, Andrica C. H. Neggers, Sebastian J. C. M. M. van Dulmen-den Broeder, Eline van den Heuvel-Eibrink, Marry M. van der Pal, Helena J. H. Versluys, A. Birgitta van der Heiden-van der Loo, Margriet Louwerens, Marloes Kremer, Leontien C. M. Brand, Henk S. Bresters, Dorine Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2) |
title | Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2) |
title_full | Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2) |
title_fullStr | Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2) |
title_full_unstemmed | Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2) |
title_short | Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities—A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2) |
title_sort | prevalence and risk factors for hyposalivation and xerostomia in childhood cancer survivors following different treatment modalities—a dutch childhood cancer survivor study late effects 2 clinical study (dccss later 2) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320024/ https://www.ncbi.nlm.nih.gov/pubmed/35884440 http://dx.doi.org/10.3390/cancers14143379 |
work_keys_str_mv | AT stolzejuliette prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT teepenjopc prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT raberdurlacherjudithe prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT loonenjacquelinej prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT kokjudithl prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT tissingwimje prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT devriesandricach prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT neggerssebastianjcmm prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT vandulmendenbroedereline prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT vandenheuveleibrinkmarrym prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT vanderpalhelenajh prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT versluysabirgitta prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT vanderheidenvanderloomargriet prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT louwerensmarloes prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT kremerleontiencm prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT brandhenks prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 AT brestersdorine prevalenceandriskfactorsforhyposalivationandxerostomiainchildhoodcancersurvivorsfollowingdifferenttreatmentmodalitiesadutchchildhoodcancersurvivorstudylateeffects2clinicalstudydccsslater2 |